Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Event-Driven

IKang Healthcare Group (ADR) / Event-Driven

<a href="https://www.smartkarma.com/entities/741" target="_blank" data-smartkarma-citation="entities:741:1">ikang healthcare group (adr) (KANG US)</a> 's June quarter results featured 30% revenue growth (20% in local currency) with EBITDA margin stable Y/Y at 17%. The continued solid performance removes a potential barrier to the pending buyout, but also supports the dissenters' claims that the price is too low. The shares currently trade at a 13% discount to the buyout price of US$20.60/ADS, reflecting the market's skepticism that the deal will close.We tag this Insight as Bullish because the risk/reward looks favorable if the buyers terminate the deal.

ikang healthcare group (adr) (KANG US) 's June quarter results featured 30% revenue growth (20% in local currency) with EBITDA margin stable Y/Y at 17%. The continued solid performance removes a potential barrier to the pending buyout, but also supports the dissenters' claims that the price is too low. The shares currently trade at a 13% discount to the buyout price of US$20.60/ADS, reflecting the market's skepticism that the deal will close.We tag this Insight as Bullish because the risk/reward looks favorable if the buyers terminate the deal.

IKang Healthcare Group (ADR)

Good Results Cut Both Ways